Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 5, 2002, Pages 528-534

  Goel, Sanjay ^a   Jhawer, Minaxi ^a   Rajdev, Lakshmi ^a   Hopkins, Una ^a   Fehn, Karen ^a   Baker, Cheryl ^a   Chun, Hoo G ^a   Makower, Della ^a   Landau, Leon ^a   Hoffman, Anthony ^a   Wadler, Scott ^a   Mani, Sridhar ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Capecitabine; Colorectal; CPT 11; Irinotecan; Phase I

Indexed keywords

CAPECITABINE; IRINOTECAN;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 0036796011     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200210000-00022     Document Type: Article

References (22)

1. Armand JP, Extra YM, Catimel G, et al. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996;7:837-42.
2. Armand JP, Terret C, Couteau C, et al. CPT-11: the European experience. Ann N Y Acad Sci 1996;803:282-91.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 2000;355:1041-7.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan study group. N Engl J Med 2000;343:905-14.
5. Miwa M, Uram M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-FU selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
6. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000;18:343-54.
7. Di Costanzo F, Sdrobolini A, Gasperoni S. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. Crit Rev Oncol Hematol 2000;35:101-8.
8. Zeghari-Squalli N, Misset JL, Goldwasser F. Mechanism of the in vitro interaction between SN-38 and 5-FU. Proc Am Assoc Cancer Res 1997;38:19.
9. Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil, alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994;86:1096-8.
10. Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I studies of irinotecan combined with continuous infusion 5-FU and metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993;12:575.
11. Saltz LB, Kanowitz J. Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
12. Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 1996;32:24-31.
13. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19:171-7.
14. Goh BC, Ratain MJ, Bertucci D, et al. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol 2001;19:1476-84.
15. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. New Drugs 2001:19:163-9.
16. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-611.
17. Cutler NR, Sramek JJ, Pharm D, et al. Defining the maximum tolerated dose: an update. J Clin Pharmacol 2000;40:1183-204.
18. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
19. Package insert for capecitabine (Xeloda) for dosing. Nutley, NJ: Hoffman-La Roche
20. Payne S. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992;35:1505-9.
21. Schleucher N, Tewes M, Achterrath W, et al. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first line chemotherapy in metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 2001;20:561.
22. Takeda Y, Kobayashi K, Akiyama Y, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001;92:269-75.